Ameliorating the in vivo antimalarial efficacy of artemether using nanostructured lipid carriers

References

• Aditya NP, Vathsala PG, Vieira V, Murthy RS, Souto EB. Advances in nanomedicines for malaria treatment. Adv colloid interf Sci, 2013;201:1–7.
   PubMed Web of Science ®Google Scholar
• Beloqui A, Solinís MÁ, Rodríguez-Gascón A, Almeida AJ, Préat V. Nanostructured lipid carriers: Promising drug delivery systems for future clinics. Nanomed: Nanotechnol Biol Med, 2016;12(1):143–61.
   PubMed Web of Science ®Google Scholar
• Biagini GA, Ward SA, Bray PG. Malaria parasite transporters as a drug-delivery strategy. Trends Parasitol, 2005;21(7):299–301.
   PubMed Web of Science ®Google Scholar
• Carroll RW, Wainwright MS, Kim KY, Kidambi T, Gomez ND, Taylor T, Haldar K. A rapid murine coma and behavior scale for quantitative assessment of murine cerebral malaria. PLoS One, 2010;5(10):e13124.
   PubMed Web of Science ®Google Scholar
• Charpian S, Przyborski JM. Protein transport across the parasitophorous vacuole of Plasmodium falciparum: Into the great wide open. Traffic, 2008;9(2):157–65.
   PubMed Web of Science ®Google Scholar
• Chen CC, Tsai TH, Huang ZR, Fang JY. Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: Physicochemical characterization and pharmacokinetics. Eur J Pharmaceut Biopharmaceut, 2010;74(3):474–82.
   PubMed Web of Science ®Google Scholar
• Costa P, Lobo JM. Modeling and comparison of dissolution profiles. Eur J Pharmaceut Sci, 2001;13(2):123–33.
   PubMed Web of Science ®Google Scholar
• Dai M, Reznik SE, Spray DC, Weiss LM, Tanowitz HB, Gulinello M, Desruisseaux MS. Persistent cognitive and motor deficits after successful antimalarial treatment in murine cerebral malaria. Microbes Infect, 2010;12(14):1198–207.
   PubMed Web of Science ®Google Scholar
• Das S, Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AapsPharmscitech, 2011;12(1):62–76.
   PubMed Web of Science ®Google Scholar
• Das S, Ng WK, Kanaujia P, Kim S, Tan RB. Formulation design, preparation and physicochemical characterizations of solid lipid nanoparticles containing a hydrophobic drug: Effects of process variables. Colloids Surf B: Biointerf, 2011;88(1):483–9.
   PubMed Web of Science ®Google Scholar
• Das S, Ng WK, Tan RB. Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): Development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs? Eur J Pharmaceut Sci, 2012;47(1):139–51.
   PubMed Web of Science ®Google Scholar
• Devalapally H, Chakilam A, Amiji MM. Role of nanotechnology in pharmaceutical product development. J Pharmaceut Sci, 2007;96(10):2547–65.
   PubMed Web of Science ®Google Scholar
• Fang CL, A Al-Suwayeh S, Fang JY. Nanostructured lipid carriers (NLCs) for drug delivery and targeting. Recent Patents Nanotechnol, 2013;7(1):41–55.
   PubMed Web of Science ®Google Scholar
• Freitas C, Müller RH. Effect of light and temperature on zeta potential and physical stability in solid lipid nanoparticle (SLN™) dispersions. Int J Pharmaceut, 1998;168(2):221–29.
   Web of Science ®Google Scholar
• Goodyer ID, Pouvelle B, Schneider TG, Trelka DP, Taraschi TF. Characterization of macromolecular transport pathways in malaria-infected erythrocytes. Molecul biochem Parasitol, 1997;87(1):13–28.
   PubMed Web of Science ®Google Scholar
• Gref R, Domb A, Quellec P, Blunk T, Müller RH, Verbavatz JM, Langer R. The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv Drug Deliv Rev, 1995;16(2–3):215–33.
   PubMed Web of Science ®Google Scholar
• Haque S, Md S, Alam MI, Sahni JK, Ali J, Baboota S. Nanostructure-based drug delivery systems for brain targeting. Drug Dev Ind Pharm, 2012;38(4):387–411.
   PubMed Web of Science ®Google Scholar
• Hearn J, Rayment N, Landon DN, Katz DR, de Souza JB. Immunopathology of cerebral malaria: Morphological evidence of parasite sequestration in murine brain microvasculature. Infect Immun, 2000;68(9):5364–76.
   PubMed Web of Science ®Google Scholar
• Idro R, Marsh K, John CC, Newton CR. Cerebral malaria: Mechanisms of brain injury and strategies for improved neurocognitive outcome. Pediatr Res, 2010;68(4):267–74.
   PubMed Web of Science ®Google Scholar
• Iqbal MA, Md S, Sahni JK, Baboota S, Dang S, Ali J. Nanostructured lipid carriers system: Recent advances in drug delivery. J Drug Target, 2012;20(10):813–30.
   PubMed Web of Science ®Google Scholar
• Jain K, Sood S, Gowthamarajan K. Optimization of artemether-loaded NLC for intranasal delivery using central composite design. Drug Deliv, 2015;22(7):940–54.
   PubMed Web of Science ®Google Scholar
• Jain S, Patel N, Shah MK, Khatri P, Vora N. Recent advances in lipid-based vesicles and particulate carriers for topical and transdermal application. J Pharmaceut Sci, 2017;106(2):423–45.
   PubMed Web of Science ®Google Scholar
• Joshi M, Pathak S, Sharma S, Patravale V. Design and in vivo pharmacodynamic evaluation of nanostructured lipid carriers for parenteral delivery of artemether: Nanoject. Int J Pharmaceut, 2008b;364(1):119–26.
   PubMed Web of Science ®Google Scholar
• Joshi M, Pathak S, Sharma S, Patravale V. Solid microemulsion preconcentrate (NanOsorb) of artemether for effective treatment of malaria. Int J Pharmaceut, 2008a;362(1):172–8.
   PubMed Web of Science ®Google Scholar
• Karbwang J, Laothavorn P, Sukontason K, Thiha T, Rimchala W, Na-Bangchang K, Bunnag D. Effect of artemether on electrocardiogram in severe falciparum malaria. Southeast Asian J Trop Med Public Health, 1997;28:472–5.
   PubMedGoogle Scholar
• Kayser O, Kiderlen AF. Delivery strategies for antiparasitics. Expert Opin Investigat Drugs, 2003;12(2):197–207.
   PubMed Web of Science ®Google Scholar
• Lefèvre G, Thomsen MS. Clinical pharmacokinetics of artemether and lumefantrine (Riamet®). Clin Drug Investigat, 1999;18(6):467–80.
   Web of Science ®Google Scholar
• Lin X, Li X, Zheng L, Yu L, Zhang Q, Liu W. Preparation and characterization of monocaprate nanostructured lipid carriers. Colloids Surf A: Physicochem Eng Aspects, 2007;311(1):106–11.
   Web of Science ®Google Scholar
• Martin-Banderas L, A Holgado M, L Venero J, Alvarez-Fuentes J, Fernández-Arévalo M. Nanostructures for drug delivery to the brain. Curr Med Chem, 2011;18(34):5303–21.
   PubMed Web of Science ®Google Scholar
• Maude RJ, Woodrow CJ, White LJ. Artemisinin antimalarials: Preserving the “Magic Bullet”. Drug Dev Res, 2010;71(1):12–9.
   PubMed Web of Science ®Google Scholar
• Mosqueira VC, Legrand P, Gulik A, Bourdon O, Gref R, Labarre D, Barratt G. Relationship between complement activation, cellular uptake and surface physicochemical aspects of novel PEG-modified nanocapsules. Biomaterials, 2001;22(22):2967–79.
   PubMed Web of Science ®Google Scholar
• Mosqueira VC, Loiseau PM, Bories C, Legrand P, Devissaguet JP, Barratt G. Efficacy and pharmacokinetics of intravenous nanocapsule formulations of halofantrine in Plasmodium berghei-infected mice. Antimicrobial Agents Chemother, 2004;48(4):1222–8.
   PubMed Web of Science ®Google Scholar
• Muchow M, Maincent P, Müller RH. Lipid nanoparticles with a solid matrix (SLN, NLC, LDC) for oral drug delivery. Drug Dev Ind Pharm, 2008;34(12):1394–405.
   PubMed Web of Science ®Google Scholar
• Nacer A, Movila A, Baer K, Mikolajczak SA, Kappe SH, Frevert U. Neuroimmunological blood brain barrier opening in experimental cerebral malaria. PLoS Pathogens, 2012;8(10):e1002982.
   PubMed Web of Science ®Google Scholar
• Negi LM, Jaggi M, Talegaonkar S. Development of protocol for screening the formulation components and the assessment of common quality problems of nano-structured lipid carriers. Int J Pharmaceut, 2014;461(1):403–10.
   PubMed Web of Science ®Google Scholar
• Pandey V, Vijayakumar MV, Ajay AK, Malvi P, Bhat MK. Diet‐induced obesity increases melanoma progression: Involvement of Cav‐1 and FASN. Int J Cancer, 2012;130(3):497–508.
   PubMed Web of Science ®Google Scholar
• Patil S, Joshi M, Pathak S, Sharma S, Patravale V. Intravenous β-artemether formulation (ARM NLC) as a superior alternative to commercial artesunate formulation. J Antimicrob Chemother, 2012;67(11):2713–6.
   PubMed Web of Science ®Google Scholar
• Polimeni M, Prato M. Host matrix metalloproteinases in cerebral malaria: New kids on the block against blood–brain barrier integrity? Fluids Barriers CNS, 2014;11(1):1.
   PubMedGoogle Scholar
• Radu M, Chernoff J. An in vivo assay to test blood vessel permeability. J Visualized Exp, 2013;16(73):e50062.
   Google Scholar
• Rich JT, Neely JG, Paniello RC, Voelker CC, Nussenbaum B, Wang EW. A practical guide to understanding Kaplan–Meier curves. Otolaryngol-Head Neck Surg, 2010;143(3):331–36.
   PubMed Web of Science ®Google Scholar
• Shah MK, Madan P, Lin S. Preparation, in vitro evaluation and statistical optimization of carvedilol-loaded solid lipid nanoparticles for lymphatic absorption via oral administration. Pharmaceut Dev Technol, 2014;19(4):475–85.
   PubMed Web of Science ®Google Scholar
• Shah NV, Seth AK, Balaraman R, Aundhia CJ, Maheshwari RA, Parmar GR. Nanostructured lipid carriers for oral bioavailability enhancement of raloxifene: Design and in vivo study. J Adv Res, 2016;7(3):423–34.
   PubMed Web of Science ®Google Scholar
• Siram K, Chellan VR, Natarajan T, Krishnamoorthy B, Mohamed Ebrahim HR, Karanam V, Muthuswamy SS, Ranganathan HP. Solid lipid nanoparticles of diethylcarbamazine citrate for enhanced delivery to the lymphatics: In vitro and in vivo evaluation. Expert Opin Drug Deliv, 2014;11(9):1351–65.
   PubMed Web of Science ®Google Scholar
• Sood S, Jawahar N, Jain K, Gowthamarajan K, NainarMeyyanathan S. Olanzapine loaded cationic solid lipid nanoparticles for improved oral bioavailability. Curr Nanosci, 2013;9(1):26–34.
   Web of Science ®Google Scholar
• Suputtamongkol Y, Newton PN, Angus B, Teja‐Isavadharm P, Keeratithakul D, Rasameesoraj M, Pukrittayakamee S, White NJ. A comparison of oral artesunate and artemether antimalarial bioactivities in acute falciparum malaria. Br J Clin Pharmacol, 2001;52(6):655–61.
   PubMed Web of Science ®Google Scholar
• Tamjidi F, Shahedi M, Varshosaz J, Nasirpour A. Nanostructured lipid carriers (NLC): A potential delivery system for bioactive food molecules. Innovat Food Sci Emerg Technol, 2013;19:29–43.
   Web of Science ®Google Scholar
• Teeranachaideekul V, Souto EB, Junyaprasert VB, Müller RH. Cetylpalmitate-based NLC for topical delivery of coenzyme Q10 – development, physicochemical characterization and in vitro release studies. Eur J Pharmaceut Biopharmaceut, 2007;67(1):141–8.
   PubMed Web of Science ®Google Scholar
• Thatipamula RP, Palem CR, Gannu R, Mudragada S, Yamsani MR. Formulation and in vitro characterization of domperidone loaded solid lipid nanoparticles and nanostructured lipid carriers. Daru, 2011;19(1):23.
   PubMed Web of Science ®Google Scholar
• Tiwari R, Pathak K. Nanostructured lipid carrier versus solid lipid nanoparticles of simvastatin: Comparative analysis of characteristics, pharmacokinetics and tissue uptake. Int J Pharmaceut, 2011;415(1):232–43.
   PubMed Web of Science ®Google Scholar
• Torchilin VP. Multifunctional nanocarriers. Adv Drug Deliv Rev, 2012;64:302–15.
   Web of Science ®Google Scholar
• Tran TH, Ramasamy T, Truong DH, Choi HG, Yong CS, Kim JO. Preparation and characterization of fenofibrate-loaded nanostructured lipid carriers for oral bioavailability enhancement. AAPS PharmSciTech, 2014;15(6):1509–15.
   PubMed Web of Science ®Google Scholar
• Varshosaz J, Minayian M, Moazen E. Enhancement of oral bioavailability of pentoxifylline by solid lipid nanoparticles. J liposome Res, 2010;20(2):115–23.
   PubMed Web of Science ®Google Scholar